Subtype
Malignant Glioma
CI-CAN-00003164Explore in graph →
589 active trials3 approved drugs67 evidence items
- NCIt
- C4822
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003164Explore in graph →
Clinical trials
2,053 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (324)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00613132 | Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG | completed | Phase 1 | 78 | Annick DesjardinsOTHER | 1 | Feb 20, 2013 | clinicaltrials |
| NCT00613223 | Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas | completed | Phase 1 | 49 | Annick DesjardinsOTHER | 1 | Feb 20, 2013 | clinicaltrials |
| NCT00354913 |
| Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma |
| completed |
| Phase 2 |
| 21 |
| Duke UniversityOTHER |
| 1 |
| Jan 18, 2013 |
| clinicaltrials |
| NCT00030498 | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction | completed | Phase 1 | 75 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00190424 | Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma | completed | Phase 2 | 80 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 13, 2012 | clinicaltrials |
| NCT00613054 | Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma | completed | Phase 1 | 27 | Annick DesjardinsOTHER | 1 | Dec 5, 2012 | clinicaltrials |
| NCT00606008 | A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma | completed | Phase 2 | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 19, 2012 | clinicaltrials |
| NCT01200134 | HYPONCO - Hypoxia in Brain Tumors(HYPONCO) | completed | Phase 2 | 39 | University Hospital, CaenOTHER | 1 | Nov 19, 2012 | clinicaltrials |
| NCT00409214 | Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma | completed | Phase 2 | 18 | Light Sciences OncologyINDUSTRY | 1 | Nov 16, 2012 | clinicaltrials |
| NCT01251484 | BIBF 1120 in Recurrent Glioblastoma Multiforme | completed | Phase 2 | 25 | Ulrik LassenOTHER | 1 | Oct 4, 2012 | clinicaltrials |
| NCT01043536 | Dose Escalation Radiotherapy With Modulation of Intensity and Integrated Boost (SIB-IMRT) in the Treatment of Glioblastomas in Adults(SIB-IMRT) | completed | Phase 1 | 10 | Centre Georges Francois LeclercOTHER | 1 | Sep 25, 2012 | clinicaltrials |
| NCT01294735 | Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1) | completed | Phase 1 | 19 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 15, 2012 | clinicaltrials |
| NCT01089868 | Usefulness of Therapy Monitoring by Means of [(18)F]Fluoroethyltyrosine-Positron Emission Tomography (FET-PET) in Glioblastoma Multiforme Patients | completed | — | 79 | Ludwig-Maximilians - University of MunichOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT01240460 | Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection | completed | Phase 1 | 40 | SanofiINDUSTRY | 1 | Jul 27, 2012 | clinicaltrials |
| NCT00624728 | Assessment of 18FLT PET-CT for Volume Definition of High-grade Gliomas (GLIO-TEP)(GLIO-TEP) | completed | Phase 1 / Phase 2 | 21 | University Hospital, BordeauxOTHER | 1 | May 4, 2012 | clinicaltrials |
| NCT00379470 | Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) | completed | Phase 3 | 236 | NovoCure Ltd.INDUSTRY | 7 | May 1, 2012 | clinicaltrials |
| NCT01167322 | Study of NPC-07 for Fluorescence-guided Resection of Malignant Gliomas | completed | Phase 3 | 45 | NobelpharmaINDUSTRY | 1 | Apr 27, 2012 | clinicaltrials |
| NCT00132158 | ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors | completed | Phase 1 | 19 | St. Jude Children's Research HospitalOTHER | 1 | Apr 17, 2012 | clinicaltrials |
| NCT01285414 | Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 5 | Myrexis Inc.INDUSTRY | 1 | Apr 11, 2012 | clinicaltrials |
| NCT00777686 | Measuring Non-Enhancing Glioblastoma Progression | completed | — | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 30, 2012 | clinicaltrials |
| NCT00412542 | Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas | completed | Phase 2 | 78 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 28, 2012 | clinicaltrials |
| NCT00036569 | A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Feb 13, 2012 | clinicaltrials |
| NCT00973557 | The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function | completed | — | 6 | Cedars-Sinai Medical CenterOTHER | 1 | Feb 7, 2012 | clinicaltrials |
| NCT00071539 | Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors | completed | Phase 2 | 56 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 0 | Jan 20, 2012 | clinicaltrials |
| NCT00504660 | 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients | completed | Phase 2 | 75 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 11, 2012 | clinicaltrials |
| NCT01502241 | Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly(Methusalem) | completed | Phase 3 | 412 | Heidelberg UniversityOTHER | 2 | Dec 30, 2011 | clinicaltrials |
| NCT00817284 | Bevacizumab and Irinotecan or Bevacizumab and Temozolomide With Concomitant Radiotherapy for Primary Glioblastoma Multiforme (GBM) | completed | Phase 2 | 60 | Ulrik LassenOTHER | 1 | Nov 30, 2011 | clinicaltrials |
| NCT00892931 | Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme | completed | Phase 2 | 56 | Myrexis Inc.INDUSTRY | 1 | Oct 14, 2011 | clinicaltrials |
| NCT00715013 | Patupilone (EPO 906) in Patients With Recurrent or Progressive Glioblastoma | completed | Phase 1 / Phase 2 | 9 | University of ZurichOTHER | 0 | Sep 15, 2011 | clinicaltrials |
| NCT00509301 | Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme | completed | Phase 1 | 12 | Peregrine PharmaceuticalsINDUSTRY | 1 | Aug 5, 2011 | clinicaltrials |
| NCT00600054 | Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma | completed | Phase 2 | 44 | YM BioSciencesINDUSTRY | 3 | Jul 6, 2011 | clinicaltrials |
| NCT00089427 | IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma | completed | Phase 1 | 24 | INSYS Therapeutics IncINDUSTRY | 1 | Jul 4, 2011 | clinicaltrials |
| NCT00024557 | Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients | completed | Phase 1 | 40 | INSYS Therapeutics IncINDUSTRY | 1 | Jun 6, 2011 | clinicaltrials |
| NCT00041587 | Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma | completed | Phase 1 / Phase 2 | 80 | INSYS Therapeutics IncINDUSTRY | 3 | Jun 6, 2011 | clinicaltrials |
| NCT00064779 | Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma | completed | Phase 1 | 18 | INSYS Therapeutics IncINDUSTRY | 1 | Jun 6, 2011 | clinicaltrials |
| NCT00076986 | The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme | completed | Phase 3 | 300 | INSYS Therapeutics IncINDUSTRY | 6 | Jun 6, 2011 | clinicaltrials |
| NCT00104091 | Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors | completed | Phase 2 | 56 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 0 | May 23, 2011 | clinicaltrials |
| NCT00154375 | Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma | completed | Phase 3 | 240 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 26, 2011 | clinicaltrials |
| NCT00238797 | A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme | completed | Phase 2 | 36 | AstraZenecaINDUSTRY | 1 | Jan 21, 2011 | clinicaltrials |
| NCT01242566 | Temozolomide in Elderly Patients With KPS < 70(TAG) | completed | Phase 2 | 70 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 17, 2010 | clinicaltrials |
| NCT00800917 | A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme | completed | Phase 2 | 12 | Rigshospitalet, DenmarkOTHER | 1 | Jun 2, 2010 | clinicaltrials |
| NCT00165477 | Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 10, 2010 | clinicaltrials |
| NCT00283556 | High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma | completed | Phase 1 / Phase 2 | 30 | Kentuckiana Cancer InstituteOTHER | 1 | Jan 20, 2010 | clinicaltrials |
| NCT00503204 | Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour | completed | Phase 1 | 20 | AstraZenecaINDUSTRY | 2 | Nov 25, 2009 | clinicaltrials |
| NCT00224978 | Chloroquine for Treatment of Glioblastoma Multiforme | completed | Phase 3 | — | National Institute of Neurology and Neurosurgery, MexicoOTHER | 1 | Nov 18, 2009 | clinicaltrials |
| NCT00944801 | Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 63 | University of RegensburgOTHER | 1 | Jul 23, 2009 | clinicaltrials |
| NCT00032903 | This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Malignant Glioma. | completed | Phase 1 / Phase 2 | 59 | Sigma-Tau Research, Inc.INDUSTRY | 1 | Jun 3, 2009 | clinicaltrials |
| NCT00080054 | A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas | completed | Phase 1 | 24 | Pharmacyclics LLC.INDUSTRY | 1 | Apr 3, 2009 | clinicaltrials |
| NCT00115440 | BNCT to Treat Glioma That Has Progressed Following Radiotherapy | completed | Phase 1 / Phase 2 | 22 | Boneca CorporationINDUSTRY | 1 | Jan 28, 2009 | clinicaltrials |
| NCT00157703 | G207 Followed by Radiation Therapy in Malignant Glioma | completed | Phase 1 | 9 | MediGeneINDUSTRY | 1 | Dec 16, 2008 | clinicaltrials |
Data updated 23 days agoSource updated Feb 20, 2013source: clinicaltrials